Myriad Genetics (NASDAQ:MYGN) Stock Gets Price Target Increase from TD Cowen

Posted by Brian Himes on Nov 5th, 2026

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective boosted by equities research analysts at TD Cowen from $4.50 to $6.75 in a report issued on Thursday, Benzinga reports. The firm currently has a “hold” rating on the stock. TD Cowen‘s price objective indicates a potential upside of 9.83% from the company’s current price.

MYGN has been the topic of a number of other research reports. Weiss Ratings cut shares of Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 27th. Wells Fargo & Company set a $4.50 price objective on Myriad Genetics in a report on Tuesday, October 20th. Piper Sandler upgraded shares of Myriad Genetics from an “underweight” rating to a “neutral” rating and set a $5.00 target price for the company in a research note on Tuesday, October 20th. UBS Group initiated coverage on shares of Myriad Genetics in a research report on Wednesday, September 9th. They set a “neutral” rating and a $3.60 target price for the company. Finally, Wall Street Zen lowered Myriad Genetics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Myriad Genetics presently has a consensus rating of “Hold” and a consensus price target of $5.55.

Get Our Latest Stock Report on MYGN

Myriad Genetics Trading Up 2.1%

Shares of NASDAQ MYGN traded up $0.13 during trading hours on Thursday, hitting $6.15. The company’s stock had a trading volume of 2,492,419 shares, compared to its average volume of 1,896,531. Myriad Genetics has a 12 month low of $2.74 and a 12 month high of $8.09. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.21. The business has a 50-day simple moving average of $4.38 and a 200-day simple moving average of $4.62. The stock has a market cap of $587.86 million, a price-to-earnings ratio of -5.19 and a beta of 1.62.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The firm had revenue of $202.70 million for the quarter, compared to analyst estimates of $191.33 million. Myriad Genetics had a negative return on equity of 16.09% and a negative net margin of 13.96%. On average, analysts anticipate that Myriad Genetics will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Myriad Genetics

Several large investors have recently bought and sold shares of MYGN. Orbimed Advisors LLC purchased a new stake in Myriad Genetics during the 1st quarter valued at $562,500,000. BlackRock Inc. bought a new position in Myriad Genetics in the 2nd quarter valued at $62,184,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Myriad Genetics in the second quarter worth $8,039,000. Man Group plc purchased a new stake in Myriad Genetics in the second quarter worth $5,189,000. Finally, Bank of America Corp DE bought a new stake in shares of Myriad Genetics during the second quarter worth $5,150,000. Institutional investors own 99.02% of the company’s stock.

Key Stories Impacting Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, up 6% sequentially, and a loss of $0.11 per share—narrower than analysts’ expected $0.20 loss. Revenue also exceeded estimates. Read More.
Positive Sentiment: The company raised the midpoint of its 2026 revenue guidance, citing execution and improved revenue per test. It also agreed to sell its Prenatal Health business for $210 million, a transaction Myriad says will support strategic growth initiatives. Read More.
Neutral Sentiment: Q3 revenue was still 1% lower year over year, while test volume declined 2% year over year. Higher average revenue per test partly offset the volume weakness. Read More.
Negative Sentiment: Myriad said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential data exposure could create operational, legal, or reputational risks. Read More.

About Myriad Genetics

(Get Free Report)

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.